model updat post call po rais
lab industri headwind better fear
earlier today publish first look result link addit
takeaway encourag better expect lab volum progress
made launchpad initi mgmt comment around better margin
time management note hospit referr stabil return growth
guid assum stabl referr trend in-lin peer link howev unclear yet
favor test mix stabl commerci price contribut revenu per
requisit persist lab biz continu face pama pressur
also data industri supplier suggest downsid risk link
covanc organ revenue growth
inclus pass-through revenue mandat benefit report organ
growth number lower pass-through neg impact revenue
growth could continu put pressur organ growth esp given
tougher comp think cdd impli organ revenue growth guid includ pass-
through lower y/i revenue growth rang maintain despit
envigo deal conserv add revenue growth model
cdd revenue growth organ fx management abstain
call quarterli net book bill differ dynam vs prior two qtr
net win strong think net win like soft given sequenti
declin trailing-twelve-month net book bill bright side cdd margin
show solid improv y/i remain posit cro industri trend
continu monitor company-specif metric idiosyncrasi
tweak sale ep est rais po
forecast sale better lab sale y/i
increment rev envigo off-set lower organ covanc sale
y/i ep estimate rais po
due higher est base sotp multipl remain cautiou lab
multipl headwind covanc lumpi reiter under-perform rate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
pama protect access
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lh second-largest clinic laboratori
 intern invest acquisit
compani expand clinic diagnost
technolog offer better insul
growth rate lh also expand contract
research organ industri
acquisit covanc chiltern account
market share global
clinic lab oper highli competit
price-deflationari environ although
long-term see upsid potenti elev
lab consolid catalyz medicar
opportun monet lab data recent
multipl guidanc cut suggest visibl
limit see potenti
price object base sotp analysi weight averag
lab ebitda estimate roughli in-lin nation clinic lab median two
year forward multipl last ten year cro
ebitda estimate in-lin cro group current trade given recent soft
volum trend lack full understand root caus weak
believ still potenti downsid risk addit multipl contract
upsid risk faster expect materi hospit lab consolid
trend smaller expect share loss contract retail clinic opportun
monet data lab cro busi significantli faster
cro growth margin improv
downsid risk greater expect price headwind lower expect test
volum growth competit execut risk integr risk data privaci risk
regulatori risk covanc drug develop side lh like get much
credit cdd well expect given peer get
punish downsid sentiment wane segment fall short
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
